Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Researchers at the University of Cologne have found that mRNA-based COVID-19 vaccines have a lasting impact on the innate ...

“Cleveland Clinic: Millions of COVID-vaxxed will die within ‘5 years,’” the headline said. This Facebook post was flagged as ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

A team of researchers has uncovered a key cellular mechanism that affects the function of mRNA vaccines and therapeutics. Their study provides the first comprehensive understanding of how mRNA ...

A preprint study posted late last week on the server medRxiv reveals that the current Moderna COVID-19 vaccine is 53% ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

FRIDAY, April 4, 2025 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has delayed the full approval of Novavax’s COVID-19 vaccine. The decision had been expected by April 1, but the ...

RNA vaccines, like COVID-19 vaccines, work better if patients are in a good mood, finds new research by Cardiff University.

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

In pediatric patients aged 6 months to 5 years, the VE of mRNA-1273 against symptomatic infection was modest after a single dose and strong after a second dose.

The surprise delay is casting new uncertainty on the fate of another vaccine awaiting FDA action: Moderna’s next-generation Covid-19 shot, called mRNA-1283, which is set for a decision by May 31.